Tyler Taigen
Electrophysiologist/Director Quality/Associate Section Head
Research Interests
Make your next move.
Prepare your application
Review drafts before you send them.
Explore related searches
About
Dr. Tyler Taigen is an Electrophysiologist and the Director of Quality at Cleveland Clinic in the United States. His research focuses on atrial fibrillation ablation techniques, the effects of contact force on ablation outcomes, and the impact of obesity on procedural results. His recent publications include studies on dual-energy lattice-tip ablation systems and the quality of life outcomes for patients post-ablation.
Articles (12)
Background While various reports described the characteristics and catheter ablation strategies for para-Hisian premature ventricular contraction (PVC), the patient population were limited in previous literatures and optimal approach remain unknown. This study sought to comprehensively assess the safety and outcomes of catheter ablation for para-Hisian PVC, with a particular focus on the safety and efficacy of ablation from aortic coronary cusps. Methods A total of 122 para-Hisian PVC cases were retrospectively included in this study. The acute and clinical outcomes of ablation, especially the success rate, the rate of conduction system injury, and the ablation site (right side, left side His bundle (HB) region, and aortic coronary cusp), were analyzed. Results Acute procedural success was achieved in 89 patients (73%). However, long-term clinical success (≥80% reduction of PVC burden) was achieved only in 52% of acute-success cases. Cusp ablation was attempted in 35 patients (31%). Cusp ablation was performed significantly more often in clinical-success cases than clinical-failed cases (38% vs.7% P = 0.005), although ablation from multiple locations was still required. In 28 of 35 cases (80%) who underwent cusp ablation, cusp ablation affected PVC by eliminating, transiently suppressing, or changing morphology. Predictors of successful cusp ablation included earlier activation at the cusp and close anatomical proximity to the earliest site at the HB region. Conduction system injury occurred in 31 cases of the entire cohort, mainly during the HB-region ablation, with only one event during cusp ablation. Conclusion In this large cohort of para-Hisian PVC ablation, an anatomical approach from the adjacent coronary cusp ablation can be considered as an effective and safe strategy. Early local activation and a close anatomical proximity between the earliest para-Hisian site and the coronary cusp region are predictors of ablation success with this approach. What is known Catheter ablation of para-Hisian premature ventricular contraction (PVC) is challenging due to the proximity to the His bundle (HB) and/or potentially intramural sources. Catheter mapping and ablation from multiple sites, including aortic coronary cusps, have been reported as potential alternative approaches, however systematic analyses of the ablation outcome and safety for para-Hisian PVC remain scarce. What the study adds Clinical-success rate of radiofrequency (RF) ablation for para-Hisian PVC was still suboptimal (52%). However, the cases undergoing cusp ablation were associated with a better success rate (85%) than those with direct ablation to the HB region alone (42%), indicating this approach may improve the outcome. The anatomical features, including PVC earliest activation site above the HB or within short distance from the coronary cusp, may predict successful PVC elimination from the coronary cusp. Conduction system injury, including minor forms, occurred in approximately 30% cases during the RF ablation near the HB region, while only one AH prolongation observed during cusp ablation, indicating superior safety of cusp ablation.
Year:
2026
Clinical outcomes of catheter ablation for atrial fibrillation (AF) are suboptimal due, in part, to challenges in achieving durable lesions. Although focal point-by-point ablation allows for the creation of any required lesion set, this strategy necessitates the generation of contiguous lesions without gaps. A large-tip catheter, capable of creating wide-footprint ablation lesions, may increase ablation effectiveness and efficiency. In a randomized, single-blind, non-inferiority trial, 420 patients with persistent AF underwent ablation using a large-tip catheter with dual pulsed field and radiofrequency energies versus ablation using a conventional radiofrequency ablation system. The primary composite effectiveness endpoint was evaluated through 1 year and included freedom from acute procedural failure and repeat ablation at any time, plus arrhythmia recurrence, drug initiation or escalation or cardioversion after a 3-month blanking period. The primary safety endpoint was freedom from a composite of serious procedure-related or device-related adverse events. The primary effectiveness endpoint was observed for 73.8% and 65.8% of patients in the investigational and control arms, respectively ( P < 0.0001 for non-inferiority). Major procedural or device-related complications occurred in three patients in the investigational arm and in two patients in the control arm ( P < 0.0001 for non-inferiority). In a secondary analysis, procedural times were shorter in the investigational arm as compared to the control arm ( P < 0.0001). These results demonstrate non-inferior safety and effectiveness of the dual-energy catheter for the treatment of persistent AF. Future large-scale studies are needed to gather real-world evidence on the impact of the focal dual-energy lattice catheter on the broader population of patients with AF. ClinicalTrials.gov identifier: NCT05120193 .
Year:
2024
BACKGROUND: Conventional focal radiofrequency catheters may be modified to enable multiple energy modalities (radiofrequency or pulsed field [PF]) with the benefit of contact force (CF) feedback, providing greater flexibility in the treatment of arrhythmias. Information on the impact of CF on lesion formation in PF ablations remains limited. METHODS: An in vivo study was performed with 8 swine using an investigational dual-energy CF focal catheter with local impedance. Experiment I: To evaluate atrial lesion formation, contiguity, and width, a point-by-point approach was used to create an intercaval line. The distance between the points was prespecified at 4±1 mm. Half of the line was created with radiofrequency energy, whereas the other half utilized PF (single 2.0 kV application with a proprietary waveform). Experiment II: To evaluate single application lesion dimensions with a proprietary waveform, discrete ventricular lesions were performed with PFA (single 2.0 kV application) with targeted levels of CF: low, 5 to 15 g; medium, 20 to 30 g; and high, 35 to 45 g. Following 1 week of survival, animals underwent endocardial/epicardial remapping, and euthanasia to enable histopathologic examination. RESULTS: Experiment I: Both energy modalities resulted in a complete intercaval line of transmural ablation. PF resulted in significantly wider lines than radiofrequency: minimum width, 14.9±2.3 versus 5.0±1.6 mm; maximum width, 21.8±3.4 versus 7.3±2.1 mm, respectively; P <0.01 for each. Histology confirmed transmural lesions with both modalities. Experiment II: With PF, lesion depth, width, and volume were larger with higher degrees of CF (depth: r=0.82, P <0.001; width: r=0.26, P =0.052; and volume: r=0.55, P <0.001), with depth increasing at a faster rate than width. The mean depths were as follows: low (n=17), 4.3±1.0 mm; medium (n=26), 6.4±1.2 mm; and high (n=14), 9.1±1.4 mm. CONCLUSIONS: Using the same focal point CF-sensing catheter, a novel PF ablation waveform with a single application resulted in transmural atrial lesions that were significantly wider than radiofrequency. Lesion depth showed a significant positive correlation with CF with depths of 6.4 mm at moderate CF.
Year:
2024
Year:
2024
Year:
2024
BACKGROUND: Catheter ablation (CA) improves clinical outcomes in patients with atrial fibrillation (AF) and heart failure (HF) with reduced ejection fraction (HFrEF). We aimed to evaluate the impact of CA on clinical and quality-of-life outcomes across HF subtypes. METHODS: All patients undergoing AF ablation at a tertiary center were enrolled in a prospective registry and included in this study (2013–2021). The primary end point was AF recurrence. Secondary end points included AF-related hospitalizations and quality-of-life outcomes. Patients were categorized according to their HF status: no HF, HFrEF, HF with mildly reduced ejection fraction (HFmrEF), and HF with preserved ejection fraction (HFpEF). RESULTS: A total of 7020 patients were included (80% no HF, 8% HFrEF, 7% HFmrEF, and 5% HFpEF). Over 3 years, the cumulative incidence of AF recurrence after ablation was as follows: HFpEF (53%), HFmrEF (41%), HFrEF (41%), and no HF (34%); P <0.01. Multivariable Cox analyses confirmed these findings using no HF group as reference (HFpEF: hazard ratio, 1.47 [95% CI, 1.21–1.78]; HFmrEF: hazard ratio, 1.23 [95% CI, 1.04–1.45]; and HFrEF: hazard ratio, 1.17 [95% CI, 1.01–1.37]; P <0.05 for all). In all groups, CA resulted in a significant reduction of AF-related hospitalization (mean rate per 1 patient-years [before and after CA]; HFpEF [1.8 versus 0.3], HFmrEF [1.1 versus 0.2], HFrEF [1.1 versus 0.2], and no HF [1 versus 0.1]; P <0.01 for each comparison) and significant improvement in quality of life as measured by both the AF symptom severity score and the AF burden score ( P <0.01 for the comparison between baseline and follow-up for each score when tested separately). CONCLUSIONS: AF recurrence rates after CA were higher in patients with HF compared with those without HF, with patients with HFpEF being at the highest risk of recurrence. Nonetheless, CA was associated with a significant reduction in AF symptoms, AF-related hospitalization, and HF symptoms in most patients irrespective of HF subtypes.
Year:
2024
Year:
2023
Background: Effects of contact force (CF) on lesion formation during pulsed field ablation (PFA) have not been well validated. The purpose of this study was to determine the relationship between average CF and lesion size during PFA using a swine-beating heart model. Methods: A 7F catheter with a 3.5-mm ablation electrode and CF sensor (TactiCath SE, Abbott) was connected to a PFA system (CENTAURI, Galvanize Therapeutics). In 5 closed-chest swine, biphasic PFA current was delivered between the ablation electrode and a skin patch at 40 separate sites in right ventricle (28 Amp) and 55 separate sites in left ventricle (35 Amp) with 4 different levels of CF: (1) low (CF range of 4–13 g; median, 9.5 g); (2) moderate (15–30 g; median, 21.5 g); (3) high (34–55 g; median, 40 g); and (4) no electrode contact, 2 mm away from the endocardium. Swine were sacrificed at 2 hours after ablation, and lesion size was measured using triphenyl tetrazolium chloride staining. In 1 additional swine, COX (cytochrome c oxidase) staining was performed to examine mitochondrial activity to delineate reversible and irreversible lesion boundaries. Histological examination was performed with hematoxylin and eosin and Masson trichrome staining. Results: Ablation lesions were well demarcated with triphenyl tetrazolium chloride staining, showing (1) a dark central zone (contraction band necrosis and hemorrhage); (2) a pale zone (no mitochondrial activity and nuclear pyknosis, indicating apoptosis zone); and a hyperstained zone by triphenyl tetrazolium chloride and COX staining (unaffected normal myocardium with preserved mitochondrial activity, consistent with reversible zone). At constant PFA current intensity, lesion depth increased significantly with increasing CF. There were no detectable lesions resulting from ablation without electrode contact. Conclusions: Acute PFA ventricular lesions show irreversible and reversible lesion boundaries by triphenyl tetrazolium chloride staining. Electrode-tissue contact is required for effective lesion formation during PFA. At the same PFA dose, lesion depth increases significantly with increasing CF.
Year:
2023
Year:
2023
Year:
2023
Year:
2023
Year:
2023
Collaborators (4)
Thomas Callahan
Staff
Cleveland Clinic
Mina K. Chung
-
Kenneth Mayuga
Founding Director of the Space Health Center
Cleveland Clinic
Pasquale Santangeli
Hospital of the University of Pennsylvania
Make your next move.
Prepare your application
Review drafts before you send them.